MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly
Authors' conclusion
Patient-reported outcome data support for the first time that transitioning patients randomized to iSRL (who previously responded to both OOC and iSRLs) back to OOC had a significant effect on patients' symptoms score in a prospective cohort. The MPOWERED OLE showed long-term maintenance of response and sustained safety with OOC.
Study context
- Population
- Patients with acromegaly who previously responded to and tolerated both oral octreotide capsules (OOC) and injectable octreotide/lanreotide and completed the MPOWERED core phase
- Primary endpoint
- Proportion of biochemical responders (IGF-1 < 1.3 × upper limit of normal) at end of each extension year among those entering that year as responders
- Follow-up
- End of each extension year
Methodological detailswithin-patient transition between OOC and injectable somatostatin receptor ligands (iSRLs)
- Within-patient transition between OOC and iSRLs
Primary result
As reported in the abstract
Biochemical responders
Responders at year 1 extension end (monotherapy and combination therapy)
52 of 58
89.7%; 95% CI 78.8–96.1
Responders in year 2
36 of 41
87.8%; 95% CI 73.8–95.9
Responders in year 3
29 of 31
93.5%; 95% CI 78.6–99.2
Further findings
Patient-reported outcomes after transition from iSRLs to OOC
- Improved treatment convenience/satisfaction and symptom control reported
Safety
- Withdrew owing to treatment failure
- 1 patient
- No new or unexpected safety signals
Original publication
MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly. J Clin Endocrinol Metab. Published 16 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →